SEC Comment Letter 0000000000-23-008983 to Actinium Pharmaceuticals, Inc. (ATNM) (CIK 0001388320) (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM) (CIK 0001388320)
Date: Aug. 17, 2023 · CIK: 0001388320 · Accession: 0000000000-23-008983
AI Filing Summary & Sentiment
File numbers found in text: 333-273911
Letter
United States securities and exchange commission logo August 17, 2023 Sandesh Seth Chairman and Chief Executive Officer Actinium Pharmaceuticals, Inc. 100 Park Ave., 23rd Floor New York, NY 10017 Re:Actinium Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 11, 2023 File No. 333-273911 Dear Sandesh Seth: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jayun Koo
Show Raw Text
United States securities and exchange commission logo
August 17, 2023
Sandesh Seth
Chairman and Chief Executive Officer
Actinium Pharmaceuticals, Inc.
100 Park Ave., 23rd Floor
New York, NY 10017
Re:Actinium Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed August 11, 2023
File No. 333-273911
Dear Sandesh Seth:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jayun Koo